RU2014148172A - Способы индукции антигенспецифических регуляторных т-клеток - Google Patents
Способы индукции антигенспецифических регуляторных т-клеток Download PDFInfo
- Publication number
- RU2014148172A RU2014148172A RU2014148172A RU2014148172A RU2014148172A RU 2014148172 A RU2014148172 A RU 2014148172A RU 2014148172 A RU2014148172 A RU 2014148172A RU 2014148172 A RU2014148172 A RU 2014148172A RU 2014148172 A RU2014148172 A RU 2014148172A
- Authority
- RU
- Russia
- Prior art keywords
- cells
- antigen
- presenting
- specific
- regulatory
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 15
- 210000003289 regulatory T cell Anatomy 0.000 title claims abstract 9
- 230000001939 inductive effect Effects 0.000 title claims abstract 3
- 239000000427 antigen Substances 0.000 claims abstract 27
- 102000036639 antigens Human genes 0.000 claims abstract 27
- 108091007433 antigens Proteins 0.000 claims abstract 27
- 210000000612 antigen-presenting cell Anatomy 0.000 claims abstract 13
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract 10
- 210000004027 cell Anatomy 0.000 claims abstract 10
- 230000001640 apoptogenic effect Effects 0.000 claims abstract 7
- 230000001461 cytolytic effect Effects 0.000 claims abstract 6
- 102000043131 MHC class II family Human genes 0.000 claims abstract 4
- 108091054438 MHC class II family Proteins 0.000 claims abstract 4
- 230000006907 apoptotic process Effects 0.000 claims abstract 4
- 238000004519 manufacturing process Methods 0.000 claims abstract 3
- 210000002501 natural regulatory T cell Anatomy 0.000 claims abstract 3
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims abstract 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims abstract 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims abstract 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims abstract 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims abstract 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims abstract 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims abstract 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims abstract 2
- 230000001105 regulatory effect Effects 0.000 claims abstract 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims abstract 2
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 238000001261 affinity purification Methods 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 238000002523 gelfiltration Methods 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 210000004976 peripheral blood cell Anatomy 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000009466 transformation Effects 0.000 claims 1
- 238000011534 incubation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/19—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/22—Immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/418—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1114—T cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1121—Dendritic cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261640537P | 2012-04-30 | 2012-04-30 | |
| US61/640,537 | 2012-04-30 | ||
| PCT/EP2013/058835 WO2013164289A1 (en) | 2012-04-30 | 2013-04-29 | Methods for induction of antigen-specific regulatory t cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014148172A true RU2014148172A (ru) | 2016-06-20 |
Family
ID=48483027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014148172A RU2014148172A (ru) | 2012-04-30 | 2013-04-29 | Способы индукции антигенспецифических регуляторных т-клеток |
Country Status (13)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2540255B1 (es) | 2013-11-19 | 2016-05-12 | Tomás SEGURA MARTÍN | Método de aislamiento de cuerpos apoptóticos |
| GB201418433D0 (en) * | 2014-10-17 | 2014-12-03 | Imcyse Sa | Novel immunogenic peptides |
| US11485768B2 (en) * | 2016-04-19 | 2022-11-01 | Imcyse Sa | Immunogenic CD1d binding peptides |
| US20200048321A1 (en) * | 2017-03-24 | 2020-02-13 | Orpheus Bioscience Inc. | Pantids for treatment of autoimmune disorders |
| WO2019209073A1 (ko) * | 2018-04-27 | 2019-10-31 | 사회복지법인 삼성생명공익재단 | 세포의 자성 비드 부착을 통한 자성 기반 바이오 패닝 방법 |
| WO2021044405A2 (en) * | 2019-09-03 | 2021-03-11 | Enlivex Therapeutics Ltd | Therapeutic apoptotic cells for treatment of osteoarthritis |
| EP3915575A1 (en) * | 2020-05-29 | 2021-12-01 | Imnate Sarl | Vaccine formulations |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9249202B2 (en) * | 2006-08-11 | 2016-02-02 | Life Sciences Research Partners Vzw | Immunogenic peptides and their use in immune disorders |
| EP2245059B1 (en) | 2008-02-14 | 2017-09-20 | Life Sciences Research Partners VZW | Cd4+ t-cells with cytolytic properties |
| EP2249855B1 (en) | 2008-02-14 | 2017-03-22 | Life Sciences Research Partners VZW | Immunogenic peptides and their use in transplantation |
-
2013
- 2013-04-29 IN IN8964DEN2014 patent/IN2014DN08964A/en unknown
- 2013-04-29 WO PCT/EP2013/058835 patent/WO2013164289A1/en not_active Ceased
- 2013-04-29 US US14/397,560 patent/US20150125880A1/en not_active Abandoned
- 2013-04-29 HK HK15107486.9A patent/HK1206786A1/xx unknown
- 2013-04-29 EP EP13724528.8A patent/EP2844741A1/en not_active Withdrawn
- 2013-04-29 BR BR112014026606A patent/BR112014026606A2/pt not_active IP Right Cessation
- 2013-04-29 AU AU2013255888A patent/AU2013255888A1/en not_active Abandoned
- 2013-04-29 KR KR1020147030054A patent/KR20150028225A/ko not_active Withdrawn
- 2013-04-29 RU RU2014148172A patent/RU2014148172A/ru not_active Application Discontinuation
- 2013-04-29 JP JP2015509392A patent/JP2015518376A/ja active Pending
- 2013-04-29 CN CN201380022688.7A patent/CN104411818A/zh active Pending
- 2013-04-29 CA CA2871541A patent/CA2871541A1/en not_active Abandoned
-
2014
- 2014-10-08 ZA ZA2014/07298A patent/ZA201407298B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2871541A1 (en) | 2013-11-07 |
| CN104411818A (zh) | 2015-03-11 |
| EP2844741A1 (en) | 2015-03-11 |
| HK1206786A1 (en) | 2016-01-15 |
| WO2013164289A1 (en) | 2013-11-07 |
| IN2014DN08964A (cg-RX-API-DMAC7.html) | 2015-05-22 |
| US20150125880A1 (en) | 2015-05-07 |
| AU2013255888A1 (en) | 2014-10-23 |
| JP2015518376A (ja) | 2015-07-02 |
| ZA201407298B (en) | 2016-02-24 |
| KR20150028225A (ko) | 2015-03-13 |
| BR112014026606A2 (pt) | 2017-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014148172A (ru) | Способы индукции антигенспецифических регуляторных т-клеток | |
| Inada et al. | Helios-positive functional regulatory T cells are decreased in decidua of miscarriage cases with normal fetal chromosomal content | |
| Peters et al. | Ex vivo generation of human alloantigen-specific regulatory T cells from CD4posCD25high T cells for immunotherapy | |
| Morandi et al. | Immunogenicity of human mesenchymal stem cells in HLA-class I-restricted T-cell responses against viral or tumor-associated antigens | |
| RU2021138205A (ru) | Искусственные антигенпрезентирующие клетки и способы их применения | |
| AR107278A1 (es) | Procedimientos de producción de linfocitos t y linfocitos t producidos por ellos | |
| JP5414678B2 (ja) | ヒトのＦｏｘｐ３＋Ｔｒｅｇ細胞を迅速に分離するための方法およびキット | |
| Hefazi et al. | Regulatory T cell therapy of graft-versus-host disease: advances and challenges | |
| MX2014002771A (es) | Celulas t con memoria central anti tercera parte, metodos para producirlas y uso de las mismas en transplante y tratamiento de enfermedades. | |
| RU2013128866A (ru) | Иммуногенные пептиды для применения в профилактике и/или лечении инфекционных заболеваний, аутоиммунных заболеваний, иммунных ответов на аллогенные факторы, аллергических заболеваний, опухолей, отторжения трансплантата и иммунных ответов против вирусных векторов, используемых для генной терапии или генной вакцинации | |
| Matta et al. | Expansion of regulatory T cells in vitro and in vivo by IL-33 | |
| PH12021551038A1 (en) | Methods for isolating and expanding cells | |
| AU2007347364A1 (en) | Method for obtaining TREG-cells | |
| RU2011121630A (ru) | Т-клетки центральной памяти против третьей стороны, способы их получения и их применение в трансплантации и лечении заболеваний | |
| ES2564789T3 (es) | Métodos para el aislamiento y la expansión de células T reguladoras derivadas de sangre de cordón | |
| Brusko et al. | Clinical application of regulatory T cells for treatment of type 1 diabetes and transplantation | |
| EP2689009A1 (en) | Method for using regulatory t cells in therapy | |
| CN108004208A (zh) | 一种体外诱导抗原特异性t细胞的方法 | |
| AU2015290561A1 (en) | Method for generating pluripotent stem cells bearing antigen specific T cell receptor genes | |
| Fortunato et al. | IL-10-engineered dendritic cells modulate allogeneic CD8+ T cell responses | |
| Karlsson et al. | Ex vivo generation of regulatory T cells: characterization and therapeutic evaluation in a model of chronic colitis | |
| Chiba et al. | Rapid and reliable generation of invariant natural killer T‐cell lines in vitro | |
| Bastien et al. | Closing the system: Production of viral antigen-presenting dendritic cells eliciting specific CD8+ T cell activation in fluorinated ethylene propylene cell culture bags | |
| Boks et al. | IL-10/IFNγ co-expressing CD4+ T cells induced by IL-10 DC display a regulatory gene profile and downmodulate T cell responses | |
| McMurchy et al. | In vitro generation of human T regulatory cells: generation, culture, and analysis of FOXP3-transduced T cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HZ9A | Changing address for correspondence with an applicant | ||
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170802 |